CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 151 enrolled
Drug / intervention
Insertable Cardiac Monitor Implantdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01965899
NCT01965899N/ACompleted
CompareCT.gov

Reveal LINQ Usability Study

Medtronic Cardiac Rhythm and Heart Failure·interventional·Posted Oct 18, 2013·Updated Sep 23, 2016

In Brief

A clinical study evaluating Insertable Cardiac Monitor Implant for Syncope and Recurrent Symptomatic Atrial Fibrillation. Completed, enrolled 151 participants across 16 sites in 7 countries.

Detailed Summary

The purpose of the Reveal LINQ Usability Study is to assess the functionality of the Reveal LINQ insertable cardiac monitor and accompanying system in patients indicated for an insertable cardiac monitor

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSyncope, Recurrent Symptomatic Atrial Fibrillation
CountriesAustralia, Austria, Belgium, Netherlands, Russia, Slovakia, United Kingdom
Collaborators--

Timeline

N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedOct 18, 2013
Enrollment StartSep 1, 2013
Primary CompletionJul 1, 2014
Study CompletionSep 1, 2015
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 12.7 years ago

Interventions

Insertable Cardiac Monitor Implantdevice

The Reveal LINQ is a leadless device that is recommended to be implanted in the region of the thorax. Two electrodes on the body of the device continuously monitor the patient's subcutaneous ECG. The device stores ECG recordings from the patient-activated episodes and ECG recordings from automatically detected arrhythmias. Documentation of episode occurrence will be retained.